$APTX News
Last published 6mo ago
- 6mo agoAPTXDBDENOVLH+4Knoa Pharma Begins Operations as a New, Public Health-Focused Company Dedicated to Supporting Patients and Abating the Opioid CrisisBusiness WireNew Foundation Trustees and Company Board Appointed to Oversee Knoa Pharma's Public Health Purpose; Company Board to Ensure Safe and Responsible Operations Knoa Pharma LLC ("Knoa Pharma") today begins operations as an
- 2y agoAPTXBAXTentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEOBusiness WireTentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He
- 3y agoAPTXAptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic AlternativesBusiness WireAptinyx Inc. (NASDAQ:APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates In March, Aptinyx completed an analysis of the data from the
- 3y agoAPTXAptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate UpdateBusiness WireNYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company will
- 3y agoAPTXAptinyx to Present at the SVB Securities Global Biopharma ConferenceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president &
- 4y agoAPTXPreclinical Data from Aptinyx's NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for NeuroscienceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster presentations at the
- 4y agoAPTXAptinyx Reports Third Quarter 2022 Financial Results and Recent HighlightsBusiness WireCompany expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash
- 4y agoAPTXClinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH GrantBusiness WireNIH HEAL Initiative grant, administered by NIDA, funds preclinical and clinical studies of NYX-783 in opioid use disorder Preclinical studies demonstrate NYX-783 has promising activity and safety profile relevant to
- 4y agoAPTXAptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022Business WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference
- 4y agoAPTXAptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy BodiesBusiness WireResults from the Phase 2 study are expected in 1Q 2023 Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion
- 4y agoAPTXAptinyx Reports Results from Phase 2b Study of NYX-2925 in FibromyalgiaBusiness WireNYX-2925 did not achieve the primary endpoint of the study Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results fro
- 4y agoAPTXAptinyx Reports Second Quarter 2022 Financial Results and Recent HighlightsBusiness WireCompany expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disor
- 4y agoAPTXAptinyx Inc. (APTX) Q2 2022 Earnings Call TranscriptEarnings Call TranscriptsAPTX earnings call for the period ending June 30, 2022.
- 4y agoAPTXAptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022Business WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday
- 4y agoAPTXAptinyx to Participate in H.C. Wainwright 1st Annual Mental Health ConferenceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 1st Annual Mental Healt
- 4y agoAPTXAptinyx to Participate in H.C. Wainwright Global Investment ConferenceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Confe
- 4y agoAPTXAptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual MeetingBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical studies of NYX-783 in models of post-traumatic
- 4y agoAPTXAptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical ProgressBusiness WireCurrent cash position of > $100 million expected to fund operations into 2024 and enable readouts from all three ongoing Phase 2 studies Data readout from Phase 2b study of NYX-2925 in fibromyalgia expected in early to mid 3Q 2022 Data readout fro
- 4y agoAPTXAptinyx Inc. (APTX) Q1 2022 Earnings Call TranscriptEarnings Call TranscriptsAPTX earnings call for the period ending March 31, 2022.
- 4y agoAPTXAptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual MeetingBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented data from preclinical studies of NYX-783 in models of post-traumatic stre
- 4y agoAPTXAptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022Business WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday
- 4y agoAPTXAptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783Business WirePreclinical data support the continued clinical development of NYX-783 as a novel mechanistic approach for treating post-traumatic stress disorder (PTSD) NYX-783 is currently under evaluation in a Phase 2b study in patients with PTSD Aptinyx Inc.
- 4y agoAPTXAptinyx Reports Results from Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral NeuropathyBusiness WireNYX-2925 did not achieve the primary endpoint of the study Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results fro
- 4y agoAPTXAptinyx Reports Fourth Quarter and Full Year 2021 Results and HighlightsBusiness WireData readouts from Phase 2b studies of NYX-2925 in painful DPN and fibromyalgia expected in April 2022 and early to mid 3Q 2022, respectively Ongoing Phase 2 study in cognitive impairment expected to read out in late 2022 or 1Q 2023 Initiated Phas
- 4y agoAPTXAptinyx Inc. (APTX) Q4 2021 Earnings Call TranscriptEarnings Call TranscriptsAPTX earnings call for the period ending December 31, 2021.
- 4y agoAPTXAptinyx to Report Fourth Quarter and Full Year 2021 Financial Results on Wednesday, March 23, 2022Business WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Wednesda
- 4y agoAPTXAptinyx to Participate in the 42nd Annual Cowen Health Care ConferenceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participa
- 4y agoAPTXAptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in FibromyalgiaBusiness WireResults from the Phase 2b study are expected in early to mid 3Q 2022 Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced t
- 4y agoAPTXAptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development ProgramsBusiness WireLive webcast today beginning at 10:00 a.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, will host a virtual portfolio review eve
- 4y agoAPTXAptinyx to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participa
- 4y agoAPTXAptinyx Announces Formation of Scientific Advisory BoardBusiness WireLeading experts in neuroscience will provide guidance to support the advancement of Aptinyx's novel NMDA receptor modulation platform and pipeline Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therap
- 4y agoAPTXAptinyx Highlights Key Goals and Anticipated Development Milestones for 2022Business WireCatalyst-rich year with data readouts expected from three Phase 2 studies across chronic pain and cognitive impairment development programs Advancing PTSD development program with initiation of Phase 2b studies Strong balance sheet expected to fun
- 4y agoAPTXAptinyx to Host Virtual Portfolio Review Event on February 9th, 2022Business WireEvent will review the company's pipeline of clinical development programs, with a deep dive on NYX-2925 and chronic pain Featured presentation by Dr. Richard Rauck, board certified physician in pain medicine and anesthesiology at Carolinas Pain Insti
- 4y agoAPTXAptinyx Initiates Phase 2b Study of NYX-783 in Patients with Post-Traumatic Stress DisorderBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the initiation of a Phase 2b study evaluating 50 mg QD of NYX-783 in 300
- 4y agoAPTXAptinyx to Present at the 40th Annual J.P. Morgan Healthcare ConferenceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will present a
- 4y agoAPTXAptinyx to Participate in Piper Sandler 33rd Annual Virtual Healthcare ConferenceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a fireside chat at the Piper
- 5y agoAPTXAptinyx Reports Third Quarter 2021 Financial Results and Recent HighlightsBusiness WireCompleted enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022 Phase 2b fibromyalgia study and exploratory Phase 2 cognitive impairment study remain on track for re
- 5y agoAPTXAptinyx Inc. (APTX) Q3 2021 Earnings Call TranscriptEarnings Call TranscriptsAPTX earnings call for the period ending September 30, 2021.
- 5y agoAPTXAptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral NeuropathyBusiness WireResults from the Phase 2b study are expected in early to mid 2Q 2022 Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced t
- 5y agoAPTXAptinyx to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021Business WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday,
- 5y agoAPTXAptinyx Appoints Gilmore O'Neill, M.B., M.M.Sc., to Board of DirectorsBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O'Neill, M.B., M.M.Sc., to the company's board of direct
- 5y agoAPTXAptinyx to Participate in 2021 Cantor Virtual Global Healthcare ConferenceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in
- 5y agoAPTXAptinyx Secures $50 Million Growth Capital Credit Facility from K2 HealthVenturesBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreeme
- 5y agoAPTXAptinyx to Participate in H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright 23rd Annual Global Inve
- 5y agoAPTXAptinyx Reports Second Quarter 2021 Financial Results and Business HighlightsBusiness WireEnrollment on track in both Phase 2b chronic pain studies with NYX-2925—data readouts expected 1H 2022 Enrollment on track in Phase 2 cognitive impairment study with NYX-458—data readout expected 2H 2022 Completed FDA meeting on NYX-783 develo
- 5y agoAPTXAptinyx Inc. (APTX) Q2 2021 Earnings Call TranscriptEarnings Call TranscriptsAPTX earnings call for the period ending June 30, 2021.
- 5y agoAPTXAptinyx to Participate in 2021 Wedbush PacGrow Healthcare Virtual ConferenceBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the "Brain
- 5y agoAPTXAptinyx to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021Business WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, August 10
- 5y agoAPTXAptinyx to Participate in William Blair Biotech Focus Conference 2021Business WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in the Update
- 5y agoAPTXAptinyx to Participate in Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry SummitBusiness WireAptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that management will participate in a fireside chat at the Cowen Psychedelics & Nov